We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
THE SATOR PLATFORM for the Comprehensive Treatment of Metastatic Cancers:
PLATFORM concept of PANELS of nonengineered, nonpathogenic SATOR viruses proven in a variety of human cancers in cell culture, mouse xenograft models, and via human compassionate use studies.
Pretreatment testing with efficacy–predicting COMPANION DIAGNOSTICS minimizes treatment of non–responders.
No serious adverse events reported; substantial life extension achieved.
Efficient US regulatory pathway due to choice of orphan indication ovarian cancer.
Comprehensive worldwide patent protection applied for.
Complete $40 million Series A private financing.
INTERACT meeting with FDA.
Orphan drug designation submission to US FDA and European EMA.
cGMP manufacturing and preclinical testing of 3 lead candidate SATOR viruses; development and validation of 3 efficacy–predicting companion diagnostics.
IND preparation and filing for 3 SATOR viruses.
Conduct Phase 1b patient study in ovarian cancer.